Getting into a partnership at this stage would be a terrible move. Any deal now would be a Lowball offer, say 10M cash upfront for a right to the future of this drug. Say goodbye to any better deals following readouts when the potential of this drug to be a MSA and defacto PD modifying drug (if it works) will be apparent.
as long as they get to readout, even if they are running on financial fumes, I am happy.
- Forums
- ASX - By Stock
- ATH
- Ann: Appendix 4E Preliminary Final Report
ATH
alterity therapeutics limited
Add to My Watchlist
4.55%
!
1.1¢

Ann: Appendix 4E Preliminary Final Report, page-11
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.1¢ |
Change
-0.001(4.55%) |
Mkt cap ! $95.83M |
Open | High | Low | Value | Volume |
1.1¢ | 1.1¢ | 1.1¢ | $9.29K | 855.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
34 | 14615464 | 1.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.1¢ | 13635816 | 11 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
34 | 14615464 | 0.010 |
28 | 26405228 | 0.009 |
16 | 28051963 | 0.008 |
14 | 24068106 | 0.007 |
15 | 9628518 | 0.006 |
Price($) | Vol. | No. |
---|---|---|
0.011 | 13635816 | 11 |
0.012 | 39086691 | 32 |
0.013 | 9270187 | 17 |
0.014 | 13198180 | 8 |
0.015 | 2059976 | 9 |
Last trade - 10.32am 18/06/2025 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online